2024-10-18
Between October 12 and 18, a total of 11 global licensing and cooperation deals were signed. In the China biotech sector, there was one notable out-licensing deal between BaiyuTechnology Pharmaceutical and Novartis for a small molecule anti-tumor drug, with a total deal value of $1.17 billion, including an upfront payment of $70 million.
On a global scale, 10 additional licensing and cooperation deals were finalized. The largest deal of the week was the option, cooperation, and licensing agreement between TrianaBiomedicines and Pfizer for preclinical molecular glue degraders, valued at $1.549 billion, including a $49 million upfront payment.
10月12-18日，全球医药市场共签署了11项资产授权和合作协议。
中国市场仅达成1项出海交易。百裕制药向诺华授权一款小分子抗肿瘤药物，首付款7000万美元，总价值11.7亿美元。
国际市场上，共签署了10项资产授权和合作协议。最大的一笔交易是辉瑞与TrianaBiomedcines达成合作开发新型分子胶降解剂，首付款4900万美元，总价值15.49亿美元。
2. Licensing Deals
2a. China section
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
5. 2019-2023 China Innovative Drug Licensing Transactions
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions. For more information, please visit http://www.yafocapital.com
ACCESS CHINA
Event Name:
2024-09 药通中国秋季路演，线上&云南
2024-09 ACCESS CHINA Autumn Roadshow, Virtual & Yunnan
2025-01 药通中国论坛@JPM，线上&旧金山
2025-01 ACCESS CHINA @ JPM Week, Virtual & San Francisco
BioToChina.org 